Impact of Lidocaine Administration on Postoperative Complications During Lung Resection Surgery
Lung Diseases, Lung Inflammation, Lung Injury, Acute
About this trial
This is an interventional prevention trial for Lung Diseases focused on measuring lidocaine, postoperative complications, thoracic surgery
Eligibility Criteria
Inclusion Criteria:
- Patients of both sexes undergoing lung resection surgery at the Thoracic Surgery Service at the Gregorio Maranón hospital.
- Patients who voluntarily accept to participate in the study and sign the informed consent
- Age> 18 years and legally capable
- Scheduled surgery.
- Functional respiratory tests with forced expiratory volume at one second > 50% or forced vital capacity > 50% preoperatively performed on these patients routinely.
- Not having been on chronic treatment with oral corticosteroids or immunosuppressants three months before surgery.
- Patients without previous history of liver disease.
Exclusion Criteria:
- Pregnancy and lactation
- Known hypersensitivity to amide-type local anesthetics.
- Transfusion of blood products in the previous 10 days.
- Impossibility of performing mechanical ventilation for pulmonary protection.
Sites / Locations
- Hospital Gregorio Maranon
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Lidocaine IV
Lidocaine PV
no lidocaine
Group 1: intravenous lidocaine and paravertebral saline (SF). In this group during intraoperative anesthetic maintenance, a continuous intravenous infusion of lidocaine at 1.5mg/kg/h until the end of surgery and perfusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1ml/kg/h will be administered.
Group 2: intravenous SF and paravertebral lidocaine. During anesthesia maintenance, a continuous intravenous infusion of 0.9% SF and an infusion of 2% lidocaine will be administered through the intraoperative paravertebral catheter at a rate of 0.1 ml/kg/h.
Group 3: intravenous remifentanil and paravertebral SF. During the maintenance of anesthesia, a continuous intravenous infusion of remifentanil at a rate of 0.1 mg/kg/min until the end of surgery and an infusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1 ml / kg / h.